This line from Cuban is not a temporary statement, but continues the existing strategy of Cost Plus Drugs: direct manufacturing, transparent markups, and bypassing intermediaries. Public data shows that since its establishment in 2022, the company has entered the market with a fixed markup model and has built its own production facilities in Dallas.

In terms of capital pathways, he is betting on the "awakening of payers" rather than just retail growth. This means that the real customers are not just patients, but self-insured companies, state governments, and large buyers willing to bypass traditional pharmacy benefit management systems; once these large clients switch, price pressure will spread throughout the entire market along the procurement chain.

Historically, this is more akin to turning the pharmaceutical supply chain into a direct supply version of Costco: using scale purchasing, transparent gross margins, and self-built production to compress layers of price increases. Unlike traditional pharmaceutical companies that profit from patents, channels, and information asymmetry, this model relies on "more and more people knowing the costs."

Essentially, this is about restructuring the supply chain: healthcare costs are not just high at a single point, but the chain is too long and bargaining power is too dispersed; when manufacturing, pricing, and procurement are realigned, profits will flow back from intermediaries to the supply and buyer ends.

ABAB News · Cognitive Laws

Transparent costs will lead to a reordering of profits.
The more intermediaries, the more distorted the prices.
True cost reduction starts with changing the supply chain before discussing scale.